Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc has been navigating mixed performance influenced by market dynamics and impending changes in reimbursement structures, yet the company is positioned to achieve solid results that could lead to improved valuations. The final reimbursement rate for CY2026 was set at $127.28/cm², slightly above initial proposals, indicating a favorable environment that may enhance operating profits over time. Furthermore, as the market consolidates, Organogenesis is expected to capture increased market share, leading to further gains in stock performance against a backdrop of trading below its peers.

Bears say

Organogenesis Holdings Inc. faces a negative outlook primarily due to anticipated stagnation in fiscal year 2026, impacted by elevated research and development costs and the uncertainty surrounding potential reductions in selling, general, and administrative expenses. The company is also at risk of lower-than-expected growth in its PuraPly product line, challenges related to Medicare Part B pricing, and increased competition that could hinder market share gains due to regulatory complexities. Furthermore, anticipated difficulties with new product uptake, alongside negative clinical outcomes and the overall economic environment affecting sales forces, contribute to a declining confidence in the company's future financial performance.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.